Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...

As shown in the following overview of Whitehawk’s portfolio and ADC technology platform: The company’s three lead candidates target different cancer-associated proteins: HWK-007 targeting Protein ...

The company has a robust strategy for long-term growth, which includes the promising early-stage development of its anti-PTK7 ADC and a focus on overcoming physician conservatism in pediatric ...

In addition, it has also started testing DAY301, a new antibody-drug that targets PTK7. The drug is in Phase Ia/b dose escalation trials, meanwhile, the company struck a licensing deal with Ipsen ...

our PTK7-targeted ADC, cleared the first dose cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the Phase 1a/b clinical trial. Day One’s pivotal Phase 3 FIREFLY-2 ...

Additionally, the company has been actively participating in scientific conferences, showcasing its research and development progress, including preclinical data on its DLL3 and PTK7 programs.

and progress in ADC programs targeting Ly6E and PTK7, showcasing advancements in technology and therapeutic designs. Management reaffirmed their guidance on pipeline priorities, with the IND for ...

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at ...

It will also support initial trials of CD70-targeted PRO1160, PTK7-targeted PRO1107, and bispecific ADC PRO1286. New investors in the round included Nextech Invest, T Rowe Price Associates ...